|
US20090047255A1
(en)
*
|
2006-11-03 |
2009-02-19 |
Alphavax, Inc. |
Alphavirus and Alphavirus Replicon Particle Formulations and Methods
|
|
US20090111099A1
(en)
*
|
2007-10-27 |
2009-04-30 |
Yongsheng Ma |
Promoter Detection and Analysis
|
|
US8067241B2
(en)
*
|
2009-08-26 |
2011-11-29 |
General Electric Company |
Method and apparatus for antigen retrieval process
|
|
JP2013517798A
(ja)
*
|
2010-01-28 |
2013-05-20 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター
|
|
WO2011130119A2
(en)
|
2010-04-14 |
2011-10-20 |
Millipore Corporation |
Methods of producing high titer, high purity virus stocks and methods of use thereof
|
|
WO2012018628A1
(en)
|
2010-07-26 |
2012-02-09 |
Board Of Regents, The University Of Texas System |
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
|
|
EP2686423A4
(en)
*
|
2011-03-14 |
2015-01-28 |
Nat Res Council Canada |
METHOD FOR PRODUCING VIRUSES IN CELLS
|
|
AU2012340567B2
(en)
|
2011-11-22 |
2017-11-23 |
The Children's Hospital Of Philadelphia |
Virus vectors for highly efficient transgene delivery
|
|
WO2013090409A1
(en)
|
2011-12-12 |
2013-06-20 |
The Children's Hospital Of Philadelphia |
Large commercial scale lentiviral vector production system and vectors produced thereby
|
|
US9974850B2
(en)
|
2013-01-25 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Immunogenic compositions and uses thereof
|
|
DK3010537T3
(en)
*
|
2013-06-17 |
2018-09-24 |
De Staat Der Nederlanden Vert Door De Mini Van Vws Mini Van Volksgezondheit Welzijn En Sport |
PROCEDURE FOR PREVENTING AGGREGATION OF VIRUS COMPONENTS
|
|
US10161011B2
(en)
|
2013-11-29 |
2018-12-25 |
Takara Bio Inc. |
Method for quantifying adeno-associated virus
|
|
US10471132B2
(en)
|
2014-04-25 |
2019-11-12 |
Genethon |
Treatment of hyperbilirubinemia
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016004319A1
(en)
*
|
2014-07-02 |
2016-01-07 |
University Of Florida Research Foundation, Inc. |
Compositions and methods for purifying recombinant adeno-associated virus
|
|
SG11201703148TA
(en)
|
2014-11-05 |
2017-05-30 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
CN107207556B
(zh)
|
2014-11-14 |
2020-12-08 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
CN107428799A
(zh)
|
2015-01-13 |
2017-12-01 |
阿尔法韦士曼公司 |
纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
IL259441B2
(en)
|
2015-11-16 |
2024-01-01 |
Res Inst Nationwide Childrens Hospital |
Materials and methods for treatment of titin-based myopathies and other titinopaties
|
|
EP4215605A1
(en)
*
|
2015-12-11 |
2023-07-26 |
The Trustees of The University of Pennsylvania |
Scalable purification method for aav8
|
|
FI3436593T3
(fi)
|
2016-03-28 |
2023-03-16 |
Ultragenyx Pharmaceutical Inc |
Adenoviruksen lämpöinaktivointimenetelmiä
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
KR102652994B1
(ko)
|
2016-05-18 |
2024-04-01 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
WO2018017956A2
(en)
*
|
2016-07-21 |
2018-01-25 |
Spark Therapeutics, Inc. |
Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby
|
|
WO2018039375A1
(en)
|
2016-08-23 |
2018-03-01 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
EP3506817A4
(en)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
KR20240001721A
(ko)
|
2016-09-12 |
2024-01-03 |
제네똥 |
산-알파 글루코시다제 변이체 및 이의 용도
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
JP7051132B2
(ja)
|
2016-09-16 |
2022-04-11 |
ロイコケア・アクチェンゲゼルシャフト |
ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
|
|
AU2017391165B2
(en)
*
|
2016-11-04 |
2023-02-02 |
Takeda Pharmaceutical Company Limited |
Adeno-associated virus formulations
|
|
US10626376B2
(en)
|
2016-11-14 |
2020-04-21 |
St. Jude Children's Research Hospital |
Method for isolating and purifying adeno-associated virus particles using salt
|
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
|
US11357735B2
(en)
|
2017-02-01 |
2022-06-14 |
Centre National De La Recherche Scientifique |
Particles and compositions comprising the same for transfection
|
|
CN110914419A
(zh)
|
2017-03-10 |
2020-03-24 |
吉尼松公司 |
糖原贮积病iii的治疗
|
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
AU2018302016A1
(en)
|
2017-07-17 |
2020-02-06 |
The Regents Of The University Of California |
Trajectory array guide system
|
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2019067840A1
(en)
|
2017-09-29 |
2019-04-04 |
Voyager Therapeutics, Inc. |
RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
CA3077426A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN111566220A
(zh)
*
|
2017-11-08 |
2020-08-21 |
阿维克斯公司 |
制备病毒载体的手段和方法及其用途
|
|
EP3720500A4
(en)
*
|
2017-12-05 |
2021-08-25 |
Applied Genetic Technologies Corporation |
FORMULATION OPTIMIZATION FOR VIRAL PARTICLES
|
|
CN119770682A
(zh)
|
2018-01-31 |
2025-04-08 |
国家儿童医院研究所 |
2c型肢带型肌营养不良的基因疗法
|
|
WO2019154939A1
(en)
|
2018-02-07 |
2019-08-15 |
Genethon |
Hybrid regulatory elements
|
|
US20210010028A1
(en)
|
2018-03-06 |
2021-01-14 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
EP3784780A1
(en)
|
2018-04-27 |
2021-03-03 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
US20210214749A1
(en)
|
2018-05-16 |
2021-07-15 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
JP7478675B2
(ja)
|
2018-06-08 |
2024-05-07 |
ノバルティス アーゲー |
薬物製品の効力を測定するための細胞ベースアッセイ
|
|
EP3814492A4
(en)
|
2018-06-29 |
2022-02-23 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
MX2020014119A
(es)
|
2018-06-29 |
2021-06-18 |
Res Inst Nationwide Childrens Hospital |
Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
|
|
EP3818161A1
(en)
|
2018-07-02 |
2021-05-12 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
CN112469427A
(zh)
*
|
2018-07-11 |
2021-03-09 |
百特奥尔塔公司 |
Aav组合物
|
|
MX2021000810A
(es)
|
2018-07-24 |
2021-04-28 |
Voyager Therapeutics Inc |
Sistemas y metodos para producir formulaciones de terapia genetica.
|
|
EP4230733A1
(en)
|
2018-08-08 |
2023-08-23 |
Genethon |
Mini-gde for the treatment of glycogen storage disease iii
|
|
US20210163991A1
(en)
*
|
2018-08-10 |
2021-06-03 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
|
JP7403852B2
(ja)
|
2018-08-20 |
2023-12-25 |
ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー |
レーベル遺伝性視神経症を治療するための組成物及び方法
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
TW202039858A
(zh)
|
2019-01-18 |
2020-11-01 |
美商航海家醫療公司 |
用於生產aav顆粒之方法及系統
|
|
SG11202109113TA
(en)
|
2019-02-26 |
2021-09-29 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
|
EP3952920A1
(en)
|
2019-04-08 |
2022-02-16 |
Genethon |
Hybrid promoters for muscle expression
|
|
EP3956354A1
(en)
|
2019-04-19 |
2022-02-23 |
Genethon |
Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
|
|
US20220143115A1
(en)
|
2019-04-19 |
2022-05-12 |
Regenxbio Inc. |
Adeno-Associated Virus Vector Formulations and Methods
|
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
CA3147574A1
(en)
|
2019-07-25 |
2021-01-28 |
Novartis Ag |
Regulatable expression systems
|
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
WO2021028559A1
(en)
|
2019-08-14 |
2021-02-18 |
Leukocare Ag |
Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
|
|
US11155835B2
(en)
|
2019-08-19 |
2021-10-26 |
The Catholic University Of America |
Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
|
|
US11401530B2
(en)
|
2019-08-19 |
2022-08-02 |
The Catholic University Of America |
Bacteriophage-based artificial viruses for human genome remodeling
|
|
SI4017871T1
(sl)
|
2019-08-21 |
2024-06-28 |
Research Institute At Nationwide Children's Hospital |
Dostava alfa-sarkoglikana z adeno povezanim virusnim vektorjem in zdravljenje mišične distrofije
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3156984A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
CN114555808A
(zh)
|
2019-10-22 |
2022-05-27 |
吉尼松公司 |
嵌合多肽及其用途
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
KR102167829B1
(ko)
*
|
2020-02-10 |
2020-10-20 |
주식회사 이노테라피 |
아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
|
|
BR112022016596A2
(pt)
|
2020-02-21 |
2022-11-16 |
Akouos Inc |
Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
EP4157301A4
(en)
*
|
2020-06-02 |
2025-03-19 |
Janssen Biotech, Inc. |
Materials and methods for viral purification
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
AU2021320395A1
(en)
*
|
2020-08-07 |
2023-04-13 |
Janssen Biotech, Inc. |
Formulations for highly purified viral particles
|
|
EP4200410A1
(en)
|
2020-08-24 |
2023-06-28 |
Genethon |
C-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
EP4237545A1
(en)
|
2020-11-02 |
2023-09-06 |
BioMarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
|
WO2022122883A1
(en)
|
2020-12-09 |
2022-06-16 |
Genethon |
Lysosomal acid lipase variants and uses thereof
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
AU2022271280A1
(en)
*
|
2021-05-07 |
2023-11-09 |
Board Of Regents, The University Of Texas System |
Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
|
|
CN117897492A
(zh)
|
2021-08-04 |
2024-04-16 |
吉尼松公司 |
用于肌肉和cns中的基因表达的杂合启动子
|
|
JP2024534410A
(ja)
|
2021-09-16 |
2024-09-20 |
ノバルティス アーゲー |
新規転写因子
|
|
US12285497B2
(en)
|
2021-10-15 |
2025-04-29 |
Research Institute At Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
WO2023073526A1
(en)
|
2021-10-25 |
2023-05-04 |
Novartis Ag |
Methods for improving adeno-associated virus (aav) delivery
|
|
WO2023175584A1
(en)
|
2022-03-17 |
2023-09-21 |
Innoskel |
Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
|
|
WO2023175585A1
(en)
|
2022-03-17 |
2023-09-21 |
Innoskel |
Hybrid promoters and their use in osteolysis syndrome
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
JP2025524363A
(ja)
|
2022-06-09 |
2025-07-30 |
ジェネトン |
糖原病ｉｉｉの処置のためのｎ末端短縮型ｇｄｅ
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202426017A
(zh)
*
|
2022-11-24 |
2024-07-01 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
非包膜病毒的藥物組合物
|
|
CN121420060A
(zh)
|
2023-06-29 |
2026-01-27 |
吉尼松公司 |
用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
|
|
EP4606892A1
(en)
|
2024-02-23 |
2025-08-27 |
Merck Patent GmbH |
Methods for the production of viral particles
|